Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis

INTRODUCTION: A 28.2 μg twice-weekly formulation of teriparatide (2/W-TPD) was developed to provide comparably high efficacy for osteoporosis to a 56.5 μg once-weekly formulation while improving the safety and persistence rate. In the current study, we aimed to elucidate the real-world persistence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Ryo, Endo, Tsutomu, Takahata, Masahiko, Haraya, Kentaro, Suzuki, Hisataka, Oda, Itaru, Kanayama, Masahiro, Asano, Tsuyoshi, Shigenobu, Keiichi, Iwata, Akira, Yamada, Katsuhisa, Takeuchi, Hirohito, Ohura, Hisanori, Yoneoka, Daisuke, Iwasaki, Norimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244578/
https://www.ncbi.nlm.nih.gov/pubmed/35759143
http://dx.doi.org/10.1007/s00774-022-01347-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244578/
https://www.ncbi.nlm.nih.gov/pubmed/35759143
http://dx.doi.org/10.1007/s00774-022-01347-1

Ejemplares similares